Skip to content

Inspection Record

Glenmark Pharmaceuticals Inc USA — FDA 483 Findings

US FDAInspected 2022-05-19Published 2026-11-13 12 findingsLaboratory and QC controlsQuality unit oversightTraining and personnelProcess validationEquipment and facilityStability and storageAseptic processing and sterility assuranceDeviation, CAPA, and investigation

Inspectors Adam R Cooke · Steven A Brettler · Justin A BoydThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Laboratory and QC controls

The accuracy, sensitivity, specificity and reproducibility of test methods have not been established and documented.

2Quality unit oversight

The quality control unit lacks authority to fully investigate errors that have occurred.

3Training and personnel

Employees engaged in the manufacture and processing of a drug product lack the training required to perform their assigned functions.

4Process validation

Written production and process control procedures are not followed in the execution ofproduction and process control functions and documented at the time of performance.

5Laboratory and QC controls

Laboratory records do not include complete data derived from all tests, examinations and assay necessary to assure compliance with established specifications and standards.

6Equipment and facility

Routine calibration of equipment is not performed according to a written program designed to assure proper performance.

7Stability and storage

An adequate number of batches of each drug product are not tested nor are records of such data maintained to determine an appropriate expiration date.

8Process validation

Time limits are not established when appropriate for the completion of each production phase to assure the quality of the drug product.

9Aseptic processing and sterility assurance

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established and followed.

10Quality unit oversight

Drug product production and control records, are not reviewed and approved by the quality control unit to determine compliance with all established, approved written procedures before a batch is released or distributed.

11Deviation, CAPA, and investigation

There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.

12Aseptic processing and sterility assurance

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.

Similar findings at other companies

GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.

A record as of the US FDA document published on 2026-11-13. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Glenmark Pharmaceuticals Inc USA company profile — full historyAll US FDA findings US FDA documents, 2026 Go to Findings search
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.